127 related articles for article (PubMed ID: 18551042)
1. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.
Fan L; Goh BC; Wong CI; Sukri N; Lim SE; Tan SH; Guo JY; Lim R; Yap HL; Khoo YM; Iau P; Lee HS; Lee SC
Pharmacogenet Genomics; 2008 Jul; 18(7):621-31. PubMed ID: 18551042
[TBL] [Abstract][Full Text] [Related]
2. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.
Lal S; Sandanaraj E; Wong ZW; Ang PC; Wong NS; Lee EJ; Chowbay B
Cancer Sci; 2008 Oct; 99(10):2045-54. PubMed ID: 19016765
[TBL] [Abstract][Full Text] [Related]
3. Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.
Voon PJ; Yap HL; Ma CY; Lu F; Wong AL; Sapari NS; Soong R; Soh TI; Goh BC; Lee HS; Lee SC
Br J Clin Pharmacol; 2013 Jun; 75(6):1497-505. PubMed ID: 23116553
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
Blanco JG; Sun CL; Landier W; Chen L; Esparza-Duran D; Leisenring W; Mays A; Friedman DL; Ginsberg JP; Hudson MM; Neglia JP; Oeffinger KC; Ritchey AK; Villaluna D; Relling MV; Bhatia S
J Clin Oncol; 2012 May; 30(13):1415-21. PubMed ID: 22124095
[TBL] [Abstract][Full Text] [Related]
5. Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism.
Bains OS; Karkling MJ; Lubieniecka JM; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2010 Mar; 332(3):755-63. PubMed ID: 20007405
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3.
Schaupp CM; White CC; Merrill GF; Kavanagh TJ
Chem Biol Interact; 2015 Jun; 234():154-61. PubMed ID: 25446851
[TBL] [Abstract][Full Text] [Related]
7. Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/- mice.
Freeland MM; Angulo J; Davis AL; Flook AM; Garcia BL; King NA; Mangibin SK; Paul KM; Prosser ME; Sata N; Bentley JL; Olson LE
Anticancer Drugs; 2012 Jul; 23(6):584-9. PubMed ID: 22343424
[TBL] [Abstract][Full Text] [Related]
8. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.
Olson LE; Bedja D; Alvey SJ; Cardounel AJ; Gabrielson KL; Reeves RH
Cancer Res; 2003 Oct; 63(20):6602-6. PubMed ID: 14583452
[TBL] [Abstract][Full Text] [Related]
9. Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3).
Lakhman SS; Ghosh D; Blanco JG
Drug Metab Dispos; 2005 Feb; 33(2):254-7. PubMed ID: 15537833
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the role of the amino acid residue at position 230 for catalysis in monomeric carbonyl reductase 3.
Miura T; Itoh Y; Takada M; Tsutsui H; Yukimura T; Nishinaka T; Terada T
Chem Biol Interact; 2009 Mar; 178(1-3):211-4. PubMed ID: 18983987
[TBL] [Abstract][Full Text] [Related]
11. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver.
Kassner N; Huse K; Martin HJ; Gödtel-Armbrust U; Metzger A; Meineke I; Brockmöller J; Klein K; Zanger UM; Maser E; Wojnowski L
Drug Metab Dispos; 2008 Oct; 36(10):2113-20. PubMed ID: 18635746
[TBL] [Abstract][Full Text] [Related]
12. NOS3 895G>T and CBR3 730G>A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP.
Zhou Q; Ding W; Weng Y; Ding G; Xia G; Xu J; Xu K; Ding Q
Chemotherapy; 2018; 63(4):191-197. PubMed ID: 30125887
[TBL] [Abstract][Full Text] [Related]
13. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients.
Lal S; Wong ZW; Jada SR; Xiang X; Chen Shu X; Ang PC; Figg WD; Lee EJ; Chowbay B
Pharmacogenomics; 2007 Jun; 8(6):567-75. PubMed ID: 17559346
[TBL] [Abstract][Full Text] [Related]
14. Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified.
Breysse DH; Boone RM; Long CM; Merrill ME; Schaupp CM; White CC; Kavanagh TJ; Schmidt EE; Merrill GF
Drug Metab Dispos; 2020 Mar; 48(3):187-197. PubMed ID: 31955137
[TBL] [Abstract][Full Text] [Related]
15. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.
Hor SY; Lee SC; Wong CI; Lim YW; Lim RC; Wang LZ; Fan L; Guo JY; Lee HS; Goh BC; Tan T
Pharmacogenomics J; 2008 Apr; 8(2):139-46. PubMed ID: 17876342
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review.
Lal S; Mahajan A; Chen WN; Chowbay B
Curr Drug Metab; 2010 Jan; 11(1):115-28. PubMed ID: 20302569
[TBL] [Abstract][Full Text] [Related]
17. Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.
Varatharajan S; Abraham A; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
Eur J Clin Pharmacol; 2012 Dec; 68(12):1577-86. PubMed ID: 22562609
[TBL] [Abstract][Full Text] [Related]
18. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
[TBL] [Abstract][Full Text] [Related]
19. MUC1 568 A/G genotype-dependent cancer antigen 15-3 levels in breast cancer patients.
Kruit A; Tilanus-Linthorst MM; Boonstra JG; van Schaik RH; Grutters JC; van den Bosch JM; Ruven HJ
Clin Biochem; 2009 May; 42(7-8):662-5. PubMed ID: 19121298
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Féty R; de Bruijn E; Hempel G; Karlsson M; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH;
Clin Pharmacokinet; 2007; 46(12):1051-68. PubMed ID: 18027989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
